Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer

被引：5
|
作者：
Ripoll, Giselle V. [1 ,2 ]
Pifano, Marina [1 ]
Garona, Juan [1 ,2 ]
Alonso, Daniel F. [1 ,2 ]
机构：
[1] Natl Univ Quilmes, Dept Sci & Technol, Mol Oncol Lab, Bernal, Argentina
[2] Natl Sci & Tech Res Council CONICET, Buenos Aires, DF, Argentina
来源：
FRONTIERS IN ONCOLOGY | 2020年 / 9卷
关键词：
hormone-resistant cancer; vasopressin; relcovaptan; desmopressin; drug repurposing; DESMOPRESSIN; COMBINATION; DOCETAXEL; GROWTH;
D O I：
10.3389/fonc.2019.01490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
    Zhao, Ning
    Peacock, Stephanie O.
    Lo, Chen Hao
    Heidman, Laine M.
    Rice, Meghan A.
    Fahrenholtz, Cale D.
    Greene, Ann M.
    Magani, Fiorella
    Copello, Valeria A.
    Martinez, Maria Julia
    Zhang, Yushan
    Daaka, Yehia
    Lynch, Conor C.
    Burnstein, Kerry L.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (498)
  • [2] Preclinical evaluation of an arginine vasopressin receptor 1A (AVPR1A) antagonist in castration-resistant prostate cancer.
    Zhao, Ning
    Peacock, Stephanie
    Lo, Chen Hao
    Heidman, Laine
    Magani, Fiorella
    Rice, Meghan
    Greene, Ann
    Zhang, Yushan
    Daaka, Yehia
    Lynch, Conor
    Burnstein, Kerry
    [J]. CANCER RESEARCH, 2018, 78 (16) : 58 - 58
  • [3] LINE-1 as a therapeutic target for castration-resistant prostate cancer
    Houede, Nadine
    Piazza, Pier Vincenzo
    Pourquier, Philippe
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 1292 - 1309
  • [4] Kaiso as a novel therapeutic target in castration-resistant prostate cancer
    Lin, Huixian
    Wang, Honghe
    White, Jason
    Karanam, Balasubramanyam
    Ghebremedhin, Anghesom
    Adu-Addai, Benjaminal
    Grizzle, William
    Yates, Clayton
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [5] GALECTIN-3 IS A THERAPEUTIC TARGET FOR CASTRATION-RESISTANT PROSTATE CANCER
    Fukumori, Tomoharu
    Dondoo, Tsogt-Ochir
    Daizumoto, Kei
    Fukawa, Tomoya
    Yamamoto, Yasuyo
    Yamaguchi, Kunihisa
    Takahashi, Masayuki
    Kanayama, Hiro-omi
    [J]. JOURNAL OF UROLOGY, 2015, 193 (04): : E675 - E675
  • [6] MiRNA 34a: a therapeutic target for castration-resistant prostate cancer
    Chalanqui, Marine J.
    O'Doherty, Michelle
    Dunne, Nicholas J.
    McCarthy, Helen O.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (09) : 1075 - 1085
  • [7] Kaiso as a novel therapeutic target in castration-resistant prostate cancer (CRPC)
    Lin, Hui-Xian
    Wang, Honghe
    White, Jason
    Karanam, Balasubramanyam
    Ghebremedhin, Anghesom
    Addai, Benjamin Adu
    Grizzle, William E.
    Yates, Clayton
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [8] Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target
    Shiota, Masaki
    Yokomizo, Akira
    Naito, Seiji
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2011, 47 (01) : R25 - R41
  • [9] Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans
    Heidman, Laine M.
    Peinetti, Nahuel
    Copello, Valeria A.
    Burnstein, Kerry L.
    [J]. MOLECULAR CANCER RESEARCH, 2022, 20 (08) : 1295 - 1304
  • [10] Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer
    McLeod, Abigail B.
    Stice, James P.
    Wardell, Suzanne E.
    Alley, Holly M.
    Chang, Ching-yi
    McDonnell, Donald P.
    [J]. PROSTATE, 2018, 78 (04): : 266 - 277
12345